[go: up one dir, main page]

EP2788350B1 - Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitué par 4-alkyle en tant qu'inhibiteurs de kinases - Google Patents

Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitué par 4-alkyle en tant qu'inhibiteurs de kinases Download PDF

Info

Publication number
EP2788350B1
EP2788350B1 EP12767002.4A EP12767002A EP2788350B1 EP 2788350 B1 EP2788350 B1 EP 2788350B1 EP 12767002 A EP12767002 A EP 12767002A EP 2788350 B1 EP2788350 B1 EP 2788350B1
Authority
EP
European Patent Office
Prior art keywords
phenyl
pyrazin
cpd
dihydropyrrolo
trifluoromethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12767002.4A
Other languages
German (de)
English (en)
Other versions
EP2788350A1 (fr
Inventor
Francesco Casuscelli
Alessandra Badari
Sten Christian ORRENIUS
Claudia Piutti
Teresa Disingrini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences SRL filed Critical Nerviano Medical Sciences SRL
Priority to EP12767002.4A priority Critical patent/EP2788350B1/fr
Publication of EP2788350A1 publication Critical patent/EP2788350A1/fr
Application granted granted Critical
Publication of EP2788350B1 publication Critical patent/EP2788350B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to 4-alkyl substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives, to a process for their preparation, to the pharmaceutical compositions comprising them, and to their use as therapeutic agents, particularly in the treatment of diseases caused by dysregulated protein kinase activity, such as cancer, cell proliferative disorders, viral infections, immune disorders, neurodegenerative disorders and cardiovascular diseases.
  • diseases caused by dysregulated protein kinase activity such as cancer, cell proliferative disorders, viral infections, immune disorders, neurodegenerative disorders and cardiovascular diseases.
  • PKs protein kinases
  • PKs are also implicated in many non-malignant diseases, such as benign prostate hyperplasia, familial adenomatosis, polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.
  • non-malignant diseases such as benign prostate hyperplasia, familial adenomatosis, polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.
  • PKs are also implicated in inflammatory conditions and in the multiplication of viruses and parasites. PKs may also play a major role in the pathogenesis and development of neurodegenerative disorders.
  • PIMs are protein-serine/threonine kinases. PIM kinases are poorly expressed in normal tissues, and overexpressed or even mutated in a discrete number of human cancers, including Lymphoma, Leukaemia, Prostate, Pancreas and Gastric cancers [ Shah et al. Eur. J. Cancer, 44, 2144-51, (2008 )].
  • PIM1 and PIM2 kinases may be involved in mediating the oncogenic effects of some acute myelogenous leukemias (AML)-associated oncogenes, in particular, the oncogenic role of FLT3-mutations (ITD and KD mut., present in 30% of AMLs) and/or translocations involving the MLL gene (occurring in 20% of AMLs), [ Kumar, et al. J. Mol. Biol. 348, 183-193, (2005 )]. PIM1 is more expressed in FLT3-ITD-transformed AML cells than in WT bone marrow cells.
  • AML acute myelogenous leukemias
  • CLL chronic lymphocytic leukemia
  • DLBCL diffuse large B-cell lymphoma
  • MCL mantle cell lymphoma
  • myeloma Cohen et al. Leuk. Lymphoma 94 51 2004 , Huttmann et al Leukemia 20 1774 (2006 )].
  • PIM1 kinase In prostate cancers, oncogenic PIM1 kinase is implicated with c-Myc in carcinogenesis, and the c-MYC/Pim1 synergy is critically dependent on PIM1 kinase activity. PIM1 cooperativity with c-MYC in vivo, is explained not only on the c-MYC activity by S62 phosphorylation, but also on the evidence of neuroendocrine (NE) differentiation [ Wang J. et al. Oncogene (2010) 29, 2477-2487 ].
  • PIM and AKT/PKB seem to play partly redundant roles in mediating growth and survival of hematopoietic cells most probably due to overlapping substrates like BAD, p21WAF1/CIP1, p27KIP1, or Cot/Tpl-2 [ Choudhary et al., Mol Cell. 36 326-39 (2009 )].
  • PIM kinases have been shown to control mTOR inhibition (rapamycin) resistance, proliferation and survival. Therefore, a combination of small molecule inhibitors targeting several survival kinases might be essential for a powerful cancer therapeutic platform [ Amaravadi R., et al. J. Clin. Invest. 2005, 115 (10) 2618-24 ].
  • Oncogenic protein synthesis through eIF4E binding protein 1 (4E-BP1) seems to be mTOR-independent and controlled by PIM2.
  • a first object of the present invention is to provide a 4-alkyl substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one compound derivative represented by formula (I): wherein
  • the present invention also provides methods of synthesizing the substituted derivatives, represented by the formula (I), prepared through a process consisting of standard synthetic transformations and isomers, tautomers, hydrates, solvates, complexes, metabolites, prodrugs, carriers, N-oxides and pharmaceutically acceptable salts.
  • the present invention also provides a compound of formula (I) as defined above for use in treating diseases caused by and/or associated with dysregulated protein kinase activity, particularly ABL, ACK1, AKT1, ALK, AUR1, AUR2, BRK, BUB1, CDC7/DBF4, CDK2/CYCA, CHK1, CK2, EEF2K, EGFR1, EphA2, EphB4, ERK2, FAK, FGFR1, FLT3, GSK3 ⁇ , Haspin, IGFR1, IKK2, IR, JAK1, JAK2, JAK3, KIT, LCK, LYN, MAPKAPK2, MELK, MET, MNK2, MPS1, MST4, NEK6, NIM1, P38 ⁇ , PAK4, PDGFR, PDK1, PERK, PIM1, PIM2, PIM3, PKA ⁇ , PKC ⁇ , PLK1, RET, ROS1, SULU1, Syk, TLK2, TRKA, TRKb TYK, VEGFR2, VEGFR3, ZAP70
  • a preferred method of the present invention is to provide a compound of formula (I) as defined above for use in treating a disease caused by and/or associated with dysregulated protein kinase activity selected from the group consisting of cancer, cell proliferative disorders, viral infections, immune cell-associated diseases and disorders, neurodegenerative disorders and cardiovascular diseases.
  • Another preferred method of the present invention is to provide a compound of formula (I) as defined above for use in treating specific cellular proliferation disorders such as, for example, benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
  • specific cellular proliferation disorders such as, for example, benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
  • Another preferred method of the present invention is to provide a compound of formula (I) as defined above for use in treating immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases, for examples multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases (IBD), Crohn's disease, irritable bowel syndrome, pancreatitis, ulcerative colitis, diverticulosis, myasthenia gravis, vasculitis, psoriasis, scleroderma, asthma, allergy, systemic sclerosis, vitiligo, arthritis such as osteoarthritis, juvenile rheumatoid arthritis, ankylosing spondylitis.
  • inflammatory and autoimmune diseases for examples multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases (IBD), Crohn's disease, irritable bowel syndrome, pancreatitis, ulcerative colitis, diverticulosis, myasthenia gravis, va
  • Another preferred method of the present invention is to provide a compound of formula (I) as defined above for use in treating viral infections, in particular the prevention of AIDS development in HIV-infected individuals.
  • the methods defined above may further comprise subjecting the mammal in need thereof to a radiation therapy or chemotherapeutic regimen in combination with at least one cytostatic or cytotoxic agent.
  • the method of the present invention also provides tumor angiogenesis and metastasis inhibition as well as the treatment of organ transplant rejection and host versus graft disease.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effectve amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, carrier and/or diluent.
  • the pharmaceutical composition of the present invention may further comprise one or more chemotherapeutic - e.g. cytostatic or cytotoxic - agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents (e.g.
  • chemotherapeutic e.g. cytostatic or cytotoxic - agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor
  • angiogenesis inhibitors farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.
  • the present invention further provides an in vitro method for inhibiting protein kinase activity which comprises contacting the kinase with an effective amount of a compound of formula (I) as defined above.
  • the invention provides a product or kit comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined above, or pharmaceutical compositions thereof and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
  • the present invention includes all of the pharmaceutically acceptable salts of the compounds of this invention.
  • a stereogenic center or another form of an isomeric center is present in a compound of the present invention, all forms of such isomer or isomers, including enantiomers and diastereomers, are intended to be covered herein.
  • Compounds containing a stereogenic center may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone. In cases in which compounds have unsaturated carbon-carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention.
  • each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form.
  • aryl includes carbocyclic or heterocyclic hydrocarbons with from 1 to 2 ring moieties, either fused or linked to each other by single bonds, wherein at least one of the rings is aromatic; if present, any aromatic heterocyclic hydrocarbon also referred to as heteroaryl group, comprises a 5 to 6 membered ring with from 1 to 3 heteroatoms selected from N, O and S.
  • heterocyclyl also known as “heterocycloalkyl”
  • heterocyclyl we intend a 3- to 7-membered, saturated or partially unsaturated carbocyclic ring where one or more carbon atoms are replaced by heteroatoms such as nitrogen, oxygen and sulfur.
  • heterocyclyl groups are, for instance, pyrane, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, thiazoline, thiazolidine, dihydrofuran, tetrahydrofuran, 1,3-dioxolane, piperidine, piperazine, morpholine and the like.
  • straight or branched C 1 -C 6 alkyl hence comprehensive of C 1 -C 4 alkyl, we intend any of the groups such as, for instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, n-hexyl, and the like.
  • straight or branched C 2 -C 6 alkenyl we intend any of the groups such as, for instance, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 1-hexenyl, and the like.
  • straight or branched C 2 -C 6 alkynyl we intend any of the groups such as, for instance, ethynyl, 2-propynyl, 4-pentynyl, and the like.
  • each of the above substituent may be further substituted by one or more of the aforementioned groups.
  • polyfluorinated alkyl or alkoxy we intend any of the above straight or branched C 1 -C 6 alkyl or alkoxy groups which are substituted by more than one fluorine atom such as, for instance, trifluoromethyl, trifluoroethyl, 1,1,1,3,3,3-hexafluoropropyl, trifluoromethoxy and the like.
  • alkoxy, aryloxy, heterocyclyloxy and derivatives thereof we intend any of the above C 1 -C 6 alkyl, aryl or heterocyclyl groups linked to the rest of the molecule through an oxygen atom (-O-).
  • any group whose name is a composite name such as, for instance, arylamino has to be intended as conventionally construed by the parts from which it derives, e.g. by an amino group which is further substituted by aryl, wherein aryl is as above defined.
  • Pharmaceutically acceptable salts of the compounds of the formula (I) include the acid addition salts with inorganic or organic acids, e.g., nitric, hydrochloric, hydrobromic, sulfuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic, glycolic, fumaric, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulphonic, isethionic and salicylic acid.
  • the acid addition salt of the compounds of the invention is selected between the hydrochloride or mesylate salt.
  • LG is a suitable leaving group such as iodo, bromo, chloro, or a sulphonate group such as - OS(O) 2 CF 3 , -OS(O) 2 CH 3 or -OS(O) 2 Ph- p Me);
  • Z' and Z" are either hydrogen, C 1 -C 6 alkyl or, taken together with the oxygen atoms to which they are bonded, may form an optionally substituted 5- to 6-membered heterocycle;
  • A is a group -(CH 2 ) 2 -X-R1, wherein X is NR', R' is hydrogen or a protecting group, and R1 is as defined above;
  • R2 is an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, arylalkyl
  • a process of the present invention comprises the following steps:
  • Z' and Z" are either hydrogen, C 1 -C 6 alkyl or, taken together with the oxygen atoms to which they are bonded, may form an optionally substituted 5 to 6 membered heterocycle;
  • R2" is an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl;
  • Q is a halogen or a triflate group, or an alkylsulfonyloxy group or an arylsulfonyloxy group, such as a mesylate or a tosylate;
  • A is a group -(CH 2 ) 2 -X-R1 wherein X is -O-, and R1 is hydrogen;
  • R2 is optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3
  • a process of the present invention comprises the following steps:
  • Hal is halogen;
  • A is a group -(CH 2 ) 2 -X-R1 wherein X is -O-, and R1 is hydrogen;
  • R2 is optionally substituted aryl;
  • R3 is an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl; and
  • R4 is hydrogen.
  • a process of the present invention comprises the following steps:
  • A is a group -CH 2 -X-R1 wherein X is NR', and R' and R1 are hydrogen;
  • R2 is an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl; and R3 and R4 are hydrogen.
  • a process of the present invention comprises the following steps:
  • E is an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, heterocyclyl and -(CH 2 ) 1-2 -COOAlk
  • E 1 is an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, heterocyclyl and -(CH 2 ) 1-3 -OH
  • E 2 is an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, heterocyclyl and -(CH 2 ) 1-3 -Y
  • ALK is C 1 -C 6 alkyl
  • Y is an azide group (-N 3 ) or an amino group of formula-N(CHO) 2 , or a phtalimido or an amino group with two protecting groups of formula -N(pg) 2
  • pg is a protecting group such as tert-butylcarbamate or benzyloxy carbonyl
  • Hal is Halogen
  • A is an optionally substituted group selected
  • a process of the present invention comprises the following steps:
  • pg' is a protecting group such as p-methoxybenzyl or 2,4-dimethoxybenzyl;
  • A is an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, heterocyclyl and -(CH 2 ) 1-3 -X-R1, wherein X and R1 are as defined above;
  • R2 is an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl;
  • R3 and R4 are hydrogen.
  • an ester of formula (II) can be reacted in different ways and experimental conditions known in the art with a reducing agent.
  • a reducing agent such as sodium borohydride, lithium alluminium hydride or the like
  • a suitable solvent such as methanol, ethanol or THF
  • the reaction is conveniently performed with sodium borohydride in ethanol at room temperature to obtain a compound of formula (III).
  • a compound of formula (III) can be reacted in different ways and experimental conditions known in the art with an alcohol activating reagent, such as a sulphonylating agent.
  • an alcohol activating reagent such as a sulphonylating agent.
  • a suitable solvent for instance THF, DCM, DMF or the like
  • a suitable base such as triethylamine or diisopropylethylamine
  • the methanesulfonyl chloride as sulfonylating agent is added therein.
  • the mixture is stirred for a time of about 1 hour to about 6 hours, at a temperature ranging from about 0 °C to room temperature.
  • a compound of formula (III) is transformed into the compound of formula (V) by Mitsunobu-type reaction a widely known reaction to convert alcohol into azide.
  • Said reaction which is well known to those skilled in the art, can be accomplished using a dialkyl azodicarboxylate, such as diethylazodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD) or the like, in the presence of a trialkyl or triaryl phosphine, preferably triphenyl phosphine in the presence of an azide ion source such as nicotinyl azide (NCA) or DPPA (diphenylphosphoryl azide).
  • NCA nicotinyl azide
  • DPPA diphenylphosphoryl azide
  • the reaction can be performed with DPPA (diphenylphosphoryl azide) and diazabicycloundecene (DBU).
  • DPPA diphenylphosphoryl azide
  • DBU diazabicycloundecene
  • the reaction is performed in a convenient solvents such as aprotic solvents such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetonitrile and the like at temperatures ranging from 0°C to RT and for a time ranging from 30 minutes to about 48 hours.
  • Preferred reaction is the Suzuki reaction where the appropriate boronic derivative is used in the presence of a palladium based catalyst such as PdCl 2 (dppf) 2 CH 2 Cl 2 or Pd 2 (dba) 3 or Pd(PPh 3 ) 4 .
  • Convenient solvents include aprotic solvents such as DMF, DCM, MeOH, CH 3 CN, or in a mixture of solvents, such as dimethoxyethane and water, optionally in the presence of a base such as sodium, cesium carbonate or cesium fluoride, at a temperature ranging from room temperature to 100°C.
  • step 5b of the process the compound of the formula (VI) is reacted with a derivative of formula (XIII), through the Sonogashira coupling between the alkyne derivative of formula (XIII) and the compound of formula (VI), in the presence of suitable Pd-catalysts include Pd(PPh 3 ) 4 , Pd(PPh 3 ) 2 Cl 2 , suitable ligands include tryphenylphosphine, a base such as triethylamine and an additive such as copper(I) iodide, using N,N-dimethylformamide as the solvent, at a temperature varying from room temperature to reflux and for a time ranging between 4 hours and overnight.
  • Pd-catalysts include Pd(PPh 3 ) 4 , Pd(PPh 3 ) 2 Cl 2
  • suitable ligands include tryphenylphosphine, a base such as triethylamine and an additive such as copper(I) iodide, using
  • a compound of formula (VI) can be transformed into an organometal derivative of formula (VIa) such as an organoboron or the like.
  • Preferred organonboron compounds can be obtained for instance reacting a compound of (VI) with a suitable boron compound, such as bis(pinacolato)diboron, pinacolborane, or the like in the presence of a suitable palladium catalyst such as palladium acetate, PdCl 2 (dppf) 2 and a suitable base, such as KOAc, triethylamine and the like, in solvents such as DMF, 1,4-dioxane, dimethoxyethane, THF or the like, at temperature ranging from 20°C to reflux and for a time ranging from 30 minutes to about 24 hours.
  • a suitable boron compound such as bis(pinacolato)diboron, pinacolborane, or the like
  • a suitable palladium catalyst such as palladium acetate, PdC
  • step 5" of the process a compound of formula (VIa) is reacted with an appropriate electrophile of formula R2-Q (XIV), wherein Q is an halide or a trifluoromethansulfonate (triflate), a methansulfonate (mesylate) or a p-toluenesulfonate (tosylate) in the presence of a palladium or nickel-based catalyst, such as for instance, tetrakis (triphenylphosphine)palladium, or PdCl 2 (dppf) 2 CH 2 Cl 2 , and a suitable base, such as Cs 2 CO 3 , K 2 CO 3 , CsF, and the like.
  • a palladium or nickel-based catalyst such as for instance, tetrakis (triphenylphosphine)palladium, or PdCl 2 (dppf) 2 CH 2 Cl 2
  • a suitable base such as Cs 2 CO 3 , K 2 CO
  • step 6 of the process the compound of the formula (II) is reacted with a derivative of formula (XII), following the condition described under step 5a.
  • a compound of formula (II) can be transformed into an organometal derivative of formula (VIII) such as an organoboron or the like following the condition described under step 5'.
  • step 8 of the process a compound of formula (VIII) is reacted with an appropriate electrophile of formula R2"-Q (XIV), following the condition described under step 5".
  • step 9 of the process the direct transformation of a compound of formula (VII) into a compound of formula (I), can be performed according to methods well-known in the art to convert carboxyester groups (-COOEt) into alcohol (CH 2 OH).
  • a reducing agent such as borane, sodium or litium borohydride
  • a suitable solvent such as methanol, ethanol or THF at a temperature ranging from 0°C to room temperature for 2 to about 24 hours.
  • a compound of formula (VII) may be converted into the corresponding carboxylic acid derivative through basic or acidic hydrolysis conditions, widely known in the art.
  • the reaction is carried out with aqueous alkaline solutions such as aqueous lithium, sodium or potassium hydroxide in the presence of a suitable solvent such as a lower alcohol, THF, DMF or mixtures thereof; preferably the reaction is carried out with lithium hydroxide in THF/Methanol/water mixture, at a temperature ranging from about room temperature to about 80°C.
  • aqueous alkaline solutions such as aqueous lithium, sodium or potassium hydroxide
  • a suitable solvent such as a lower alcohol, THF, DMF or mixtures thereof
  • the reaction is carried out with lithium hydroxide in THF/Methanol/water mixture, at a temperature ranging from about room temperature to about 80°C.
  • the compound of formula (VII) could be obtained either in its acidic form or, alternatively, as a salt.
  • the obtained carboxylic acid is reacted with a condensing agent to form the corresponding mixed anhydride, by using an alkyl chloroformate such as ethyl, iso-propyl, benzyl chloroformate, or 1,1'-carbonyldiimidazole in the presence of an amine such as TEA, DIPEA, or pyridine, in a suitable solvent such as, for instance toluene, DCM, THF, DMF and the like, at room temperature.
  • a reducing agent such as sodium or litium borohydride in ethanol THF at a temperature ranging from 0°C to room temperature for 2 hours to about 24 hours.
  • the reaction of a compound of formula (VIIa) wherein R3 is hydrogen can be transformed into the corresponding compound of formula (IX) wherein R3 is halogen, preferably bromine or iodine.
  • the said reaction is performed with halogenating reagent such as NBS or NIS, in a suitable solvent such as DCM or DMF, from -10°C to room temperature in a period of time varying from 2 hours to about 18 hours.
  • the reaction is carried out under neutral conditions in the presence of iodine and silver trifluoroacetate, in DCM at a temperature ranging from 0° C to room temperature and for a time varying from 2 hours to overnight.
  • step 12 of the process the reaction of a compound of formula (X) with a reducing agent can be carried out in different ways and experimental conditions known in the art. Preferably, it is carried out following the conditions described under step 9).
  • the compound of formula (I) is obtained by using a one pot Curtius rearrangement process.
  • the one pot transformation of carboxylic acid into amine is most commonly achieved using diphenylphosphoryl azide (DPPA), in a suitable solvent such as THF, Toluene, at a temperature varying from 20°C to reflux, for about 2 hours to 48 hours.
  • DPPA diphenylphosphoryl azide
  • a compound of formula (XVII) may be prepared by reduction of a corresponding compound of formula (XVI) as herein before defined.
  • the reaction can be performed according to methods well-known in the art to convert carboxyester groups (-COOEt) into alcohol (CH 2 OH).
  • the reduction involves both the carboxyester groups that are present in the compound of formula (XVI).
  • a reducing agent such as borane, sodium or litium borohydride, or LiAlH 4
  • a suitable solvent such as methanol, ethanol or THF at a temperature ranging from 0°C to room temperature for 2 hours to about 24 hours.
  • a compound of formula (XIX) can be obtained by a two-reactions sequence from a compound of formula (XVII) in different ways and experimental conditions known in the art.
  • First the conversion of the OH group into a suitable leaving group is preferably carried out in the presence of a sulphonylating agent such as methanesulfonyl chloride, p-toluensulfonyl chloride, or trifluoromethansulfonate anhydride, in the presence of a suitable base such as triethylamine or diisopropylethylamine in a suitable solvent for instance THF, DCM, DMF or the like.
  • a sulphonylating agent such as methanesulfonyl chloride, p-toluensulfonyl chloride, or trifluoromethansulfonate anhydride
  • a suitable base such as triethylamine or diisopropylethylamine in a
  • the mixture is stirred for a time of about 1 hour to about 6 hours, at a temperature ranging from about 0 °C to room temperature.
  • the second step is preferably carried out in the presence of sodium azide, sodium di-formamide, sodium di- tert -butyldicarbamide, or potassium phthalimide, in a suitable organic solvent such as acetonitrile, DMF or a mixture thereof.
  • the reaction can be conveniently performed at a temperature ranging from room temperature to reflux, for a time varying from 1 hour to 8 hours.
  • a compound of formula (XIX) can be also obtained by Mitsunobu reaction.
  • Said reaction which is well known in the art, can be accomplished using a dialkyl azodicarboxylate, such as diethylazodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD) or the like, in the presence of a trialkyl or triaryl phosphine, preferably triphenyl phosphine in the presence of di- tert -butyldicarbamide, phthalimide, or an azide ion source such as nicotinyl azide (NCA) or DPPA (diphenylphosphoryl azide).
  • NCA nicotinyl azide
  • DPPA diphenylphosphoryl azide
  • reaction can be performed with DPPA (diphenylphosphoryl azide) and DBU.
  • Convenient solvents include aprotic solvents such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetonitrile and the like at temperatures ranging from 0°C to RT and for a time ranging from 30 minutes to about 48 hours.
  • a compound of formula (XX) can be obtained by reacting a compound of formula (XIX) in different ways and experimental conditions, which are widely known in the art of electrophilic acylation of pyrrole.
  • the reaction is performed by using trichloroacetyl chloride, in anhydrous solvent such as THF, DCM or 1,4-dioxane, in the presence of 2,6-lutidine as organic base, at reflux temperature for 6 to 24 hours.
  • a compound of formula (XXI) can be obtained by reacting a compound of formula (XX) in different ways and experimental conditions, which are widely known in the art.
  • a compound of formula (XXI) is reacted with an alkoxyde such as sodium methoxyde, sodium ethoxyde in a suitable dry solvent such as methanol, ethanol and the like, the reaction is performed at room temperature for 1 to about 4 hours.
  • an alkoxyde such as sodium methoxyde, sodium ethoxyde in a suitable dry solvent such as methanol, ethanol and the like
  • the reaction is performed at room temperature for 1 to about 4 hours.
  • E 2 is -(CH 2 ) 1-3 -Y
  • Y is an amino group of formula-N(CHO) 2 , or a phtalimido, or an amino group with two protecting group of formula N(pg) 2
  • the deprotection reaction involve also this group.
  • a compound of formula (XXIII) wherein Y is an amino group of formula-N(CHO) 2 , or a phtalimido, or an amino group with two protecting group of formula N(pg) 2 pg is a protecting group such as tert-butylcarbamate, can be transformed into a compound of formula (XXIII) in different ways and experimental conditions known in the art.
  • the deprotection is performed preferably under acidic conditions, for instance in the presence of an inorganic or organic acid such as hydrochloric, trifluoroacetic or methansulfonic acid, in a suitable solvent such as dichloromethane, 1,4-dioxane, a lower alcohol, such as methanol or ethanol, at a temperature ranging from room temperature to reflux and for a period of time ranging from about 1 hour to about 48 hours.
  • the cyclization is carried out under basic conditions such as in the presence of sodium or potassium carbonate, triethylamine, in a suitable solvent, such as THF, DCM, at a temperature ranging from room temperature to reflux and for a period of time ranging from 1 hour to about 48 hours.
  • E 2 is -(CH 2 ) 1-3 -Y
  • Y is an azide group
  • the reduction reaction involves also this group.
  • a compound of formula (XXII) wherein Y is an azide group can undergo reduction and cyclization to give a compound of formula (XXIII) in a variety of ways well known in the art as Staudinger reaction.
  • the said reaction is performed by using a trialkyl or triaryl phosphine in a suitable solvent such as THF at room temperature for 1 to about 4 hours.
  • the reaction may be carried out in the presence of di- tert -butyl-dicarbonate in different solvents such as methanol, ethanol, acetonitrile, THF, dichloromethane, in the presence of a base such as pyridine, triethylamine, DIPEA, sodium or potassium carbonate, at room temperature for a period of time ranging from 1 to about 18 hours.
  • solvents such as methanol, ethanol, acetonitrile, THF, dichloromethane
  • a base such as pyridine, triethylamine, DIPEA, sodium or potassium carbonate
  • step 23a and b of the process the transformation of a compound of formula (XXIII) into a compound of formula (I) can be carried out in different ways and experimental conditions. Preferably it is carried out in a way analogous to that reported for step 5a and 5b.
  • the compound of formula (XXV) can be prepared under different ways and conditions well known to the person skilled in the art as the nitroaldol reaction or known as Henry reaction.
  • the said reaction is a classical aldol-type reaction between an aldehyde and a nitroalkane ( Rosini, G. In Comprehensive organic Synthesis; Trost, B. M., 1996. Vol 2, pp 321-340 ).
  • the reaction is performed by mixing the aldehyde of formula (XXIV) with nitromethane, in the presence of a suitable base such as sodium or potassium tert-butoxyde, sodium or potassium hydroxide, ammonium acetate, ammonium hydroxide.
  • the reduction of a compound of formula (XXV) to obtain a compound of formula (XXVI) can be accomplished in different ways and conditions widely known in the art to reduce a nitro to an amino group.
  • the reaction is performed in a suitable solvent such as water, methanol, THF, 1,4-dioxane, DMF or a mixture thereof, in the presence of a suitable reducing agent, such as for instance, hydrogen, and hydrogenation catalyst, or by treatment with cyclohexene or 1,4-cyclohexadiene and a hydrogenation catalyst, or by treatment with tin(II) chloride, or by treatment with zinc and aqueous hydrochloric acid or acetic acid or ammonium chloride, at temperature ranging from 0°C to reflux for a time varying from about 1 hour to 48 hours.
  • the hydrogenation catalyst is usually a metal, most often palladium, which can be used as such or supported on carbon.
  • the protection of the amino group can be accomplished in a variety of ways and experimental conditions well known in the art.
  • the reaction can be accomplished by reductive amination, or by alkylation.
  • the compound of formula (XXVI) is reacted with benzaldehyde, 4-methoxy or 2,4-dimethoxy, or 3,4,5-trimethoxy-benzaldehyde, in a suitable solvent such as THF, 1,4-dioxane, DCM, DMF, in the presence of a reducing agent such as sodium cyanoborohydride, sodium triacetoxyborohydride, tetramethylammonium triacetoxyborohydride, optionally in the presence of protic acid, such as hydrochloric, acetic, trifluoroacetic, at a temperature ranging from 0°C to room temperature.
  • a suitable solvent such as THF, 1,4-dioxane, DCM, DMF
  • a reducing agent such as sodium cyanoborohydride,
  • the conversion can be accomplished by using the suitable benzyl or substituted benzyl bromide or chloride or trityl chloride in the presence of a suitable base such as, for instance, sodium, potassium or cesium carbonate, TEA, DIPEA, pyridine and the like, at a temperature ranging from 0°C to reflux.
  • a suitable base such as, for instance, sodium, potassium or cesium carbonate, TEA, DIPEA, pyridine and the like, at a temperature ranging from 0°C to reflux.
  • the conversion of the compound of formula (XXVIa) into the corresponding amido derivative of formula (XXVIII), can be carried out in a variety of ways according to conventional methods for obtaining amido derivatives from the corresponding ⁇ , ⁇ , ⁇ -trichloroketones.
  • the reaction is carried out by reaction of an amine of formula (XXVIa) with a trichloroketone derivative of formula (XXVII) in the presence of N,N- diisopropylethylamine, using dichloromethane as the solvent, for a time varying from about 2 hours to 48 hours.
  • step 28 of the process the conversion of the compound of formula (XXVIII) into the corresponding compound of formula (XXIX), can be accomplished in different ways and conditions widely known in the art.
  • a typical procedure involves 2 steps encompassing alcohol activation, and intramolecular nucleophilic displacement, that brought to the formation of the pyrazinone ring.
  • First reaction is preferably carried out by dissolving the compound of formula (XXVIII) in a suitable solvent for instance THF, DCM, DMF or the like, in the presence of a suitable base such as triethylamine or diisopropylethylamine, the sulphonylating agent such as methanesulfonyl chloride, is added therein.
  • the obtained compound is reacted in a suitable solvent for instance THF, DCM, DMF or the like, in the presence of a base such as triethylamine, diisopropylethylamine or DBU, at a temperature ranging from about room temperature to reflux, for a period of time varying from about 2 hours to about 24 hours.
  • a suitable solvent for instance THF, DCM, DMF or the like
  • a base such as triethylamine, diisopropylethylamine or DBU
  • step 30a and b of the process the transformation of a compound of formula (XXIXa) into a compound of formula (I) can be carried out in different ways and experimental conditions. Preferably it is carried out in a way analogous to that reported for step 5a and 5b.
  • the compound of formula (I) with a group -CH 2 OH is at first converted into the corresponding aldehyde by treatment with an oxidant agent such as for instance 2-lodoxybenzoic acid (IBX) in a suitable solvent such as ethyl acetate, tetrahydrofuran, and the like, at a temperature ranging from 50°C to reflux for a suitable time for instance 30 minutes to 4 hours.
  • an oxidant agent such as for instance 2-lodoxybenzoic acid (IBX) in a suitable solvent such as ethyl acetate, tetrahydrofuran, and the like, at a temperature ranging from 50°C to reflux for a suitable time for instance 30 minutes to 4 hours.
  • conversion (conv. b) of the process the conversion of the compound of formula (I) where a group - CH 2 OH is present, into the corresponding compound of formula (I) with a group -CH 2 NR'R1 wherein R1 is as defined above and R' is hydrogen, or a protecting group of formula -COOR6 wherein R6 is as defined above, can be accomplished in a number of ways and operative conditions well established among those skilled in the art. Typical procedures involve 2-3 steps encompassing alcohol activation, nucleophilic displacement, and manipulation of the post-nucleophile product to an amine.
  • the reaction is carried out with sodium azide, or azide exchange resin (Amberlite IR-400), in a suitable solvent such as acetonitrile, DMF, or a mixture thereof.
  • the reaction is performed at a temperature ranging from RT to 80 °C for 2 to about 18 hours.
  • Third step of the sequence is the reduction of the alkyl azide with reducing agents.
  • the reduction of alkyl azides to primary amines constitutes a synthetically useful process and can be accomplished with a wide variety of reagents including catalytic hydrogenation, LAH, sodium or zinc borohydride, triphenylphosphine Indium-NH 4 Cl, Iron-NH 4 Cl and Zinc-NH 4 Cl.
  • a trialkyl or triaryl phosphine is used in a suitable solvent such as THF at room temperature for 1 to about 4 hours. Therefore, the reaction will be diluted with water, optionally (Boc) 2 O anhydride is added to obtain the compound of formula (I) with a protecting group, and left on stirring for 18 hours to about 36 hours at the same temperature.
  • the reduction of the alkyl azide to primary amine can be accomplished with Zinc-NH 4 Cl, conveniently (Boc) 2 O anhydride is added to obtain the compound of formula (I) with a protecting group.
  • the reaction is performed at reflux in a mixture of solvent including 1,4-dioxane and water for 4 hours to about 8 hours.
  • conversion (conv. c) of the process the conversion of the compound of formula (I) where a group-CH 2 OH is present, into the corresponding compound of formula (I) with a group -CH 2 hal wherein hal is halogen, can be accomplished in different ways, according to conventional methods for the transformation of alcohols to alkyl halide derivatives. Activation of an alcohol towards nucleophilic displacement with halide ion can be achieved with a Mitsunobu-like procedure ( Org. React.
  • the conversion of the compound of formula (I) where a group-CH 2 OH is present, into the corresponding compound of formula (I) with a group -CH 2 NR'R1 wherein R1 and R' are hydrogen can be accomplished in a number of ways and operative conditions well established among those skilled in the art, preferably it is carried out by using a modified Staudinger procedure, wherein primary alcohols undergo a one pot conversion into the corresponding primary amines via the intermediate azide obtained by a Mitsunobu-type reaction, a widely known reaction to convert alcohol into azide.
  • the reaction is performed in a suitable solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetonitrile and the like at temperature ranging from 0°C to RT and for a time ranging from 30 minutes to about 48 hours. Therefore the Staudinger reaction is performed, a trialkyl or triaryl phosphine is used in a suitable solvent such as THF at room temperature for 1 to about 4 hours, followed by hydrolysis with addition of water, optionally (Boc) 2 O anhydride is added to obtain the compound of formula (I) with a protecting group, and left on stirring for 18 to about 36 hours at the same temperature.
  • a suitable solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, acetonitrile and the like at temperature ranging from 0°C to RT and for a time ranging from 30 minutes to about 48 hours. Therefore the Staudinger reaction is performed
  • a compound of the formula (I) wherein R3 or R4 is hydrogen is converted into the corresponding compound of formula (I) wherein R3 or R4 is halogen.
  • the said reaction is performed with halogenating reagent such as NCS, NBS, NIS, in a suitable solvent such as DCM, THF, MeOH, DMF or a mixture thereof, from -0°C to room temperature within 2 to about 18 hours.
  • halogenating reagent such as NCS, NBS, NIS
  • a suitable solvent such as DCM, THF, MeOH, DMF or a mixture thereof
  • the reaction is carried out under neutral conditions in the presence of iodine and silver trifluoroacetate, in DCM at a temperature ranging from 0° C to room temperature and for a time from 2 hours to overnight.
  • the said reaction is performed by using ZnCN or potassium hexacyanoferrate (II) as a source of cyanide in the presence of palladium (II) acetate as catalyst, sodium carbonate, potassium carbonate or cesium carbonate as base, in a suitable solvent such as DMF, N-methylpyrrolidone, or DMA, from 80°C to reflux, for a time ranging from 4 to about 24 hours ( J. Org. Chem. 2005, 70, 1508-1510 , Org. Lett., 2011, 13 (4), pp 648-651 ).
  • a suitable solvent such as DMF, N-methylpyrrolidone, or DMA
  • a compound of the formula (I) wherein R3 or R4 is halogen is converted into the corresponding compound of formula (I) wherein R3 or R4 is an optionally substituted group selected from straight or branched C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, cycloalkyl-alkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, by exploiting any of the cross-coupling reactions suitable for the formation of carbon-carbon bonds.
  • organometal reagent such as for instance organoboron (Suzuki reaction), organotin (Stille reaction), organomagnesium (Kumada reaction), organozinc, or organoalluminium, or organozirconium (Negishi reaction) and the like.
  • reaction is carried out through the Sonogashira coupling to give the corresponding compound of formula (I) in the presence of suitable Pd-catalysts include Pd(PPh 3 ) 4 , Pd(PPh 3 ) 2 Cl 2 , suitable ligands include tryphenylphosphine, and an additive such as copper(I) iodide, using N,N-dimethylformamide as the solvent, at a temperature varying from room temperature to reflux and for a time ranging between 4 hours and overnight.
  • Pd-catalysts include Pd(PPh 3 ) 4 , Pd(PPh 3 ) 2 Cl 2
  • suitable ligands include tryphenylphosphine
  • an additive such as copper(I) iodide, using N,N-dimethylformamide as the solvent
  • deprotection of the carboxylic residue into the corresponding acid can be achieved through basic or acidic hydrolysis conditions, widely known in the art.
  • the reaction is carried out with aqueous alkaline solutions such as aqueous lithium, sodium or potassium hydroxide in the presence of a suitable solvent such as a lower alcohol, THF, DMF or mixtures thereof; preferably the reaction is carried out with lithium hydroxide in THF/Methanol/water mixture, at a temperature ranging from about room temperature to about 80°C.
  • aqueous alkaline solutions such as aqueous lithium, sodium or potassium hydroxide
  • a suitable solvent such as a lower alcohol, THF, DMF or mixtures thereof
  • the reaction is carried out with lithium hydroxide in THF/Methanol/water mixture, at a temperature ranging from about room temperature to about 80°C.
  • the compound of formula (I) could be obtained either in its acidic form or, alternatively, as a salt.
  • the amidation of a carboxylic acid into the corresponding amide is carried out in the presence of ammonium chloride or a suitable primary or secondary amine of formula R1R'NH (XXX) under basic conditions, preferably with DIPEA or TEA, in a proper solvent such as dichloromethane, DMF, THF, 1,4-dioxane, or DMA, in the presence of a suitable condensing agent, for instance dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (EDC), 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine (DHBT), O-benzotriazolyltetramethylisouronium tetrafluoroborate (TBTU), benzotriazol-1-yloxytripyrrolidinophosphonium hexafluor
  • the said reaction is optionally carried out in the presence of a suitable catalyst such as the 4-dimethylaminopyridine, or in the presence of a further coupling reagent such as N-hydroxybenzotriazole.
  • a suitable catalyst such as the 4-dimethylaminopyridine
  • a further coupling reagent such as N-hydroxybenzotriazole.
  • this same reaction is also carried out, for example through a mixed anhydride method, which involves the use of an alkyl chloroformiate such as ethyl, iso-propyl, benzyl chloroformiate, in the presence of a tertiary amine such as TEA, DIPEA, or pyridine, in a suitable solvent such as, for instance toluene, DCM, THF, DMF and the like, at room temperature.
  • a suitable solvent such as, for instance toluene, DCM, THF, DMF and the like
  • this reaction is performed with a reducing agent, such as for instance, sodium cyanoborohydride, sodium triacetoxyborohydryde, or tetramethylamonium triacetoxyborohydride in presence of an acid or basic catalyst, such as for instance acetic acid, trifluoroacetic acid, zinc chloride, titanium(IV) chloride or TEA, DIPEA in a suitable solvent such as tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, or mixtures thereof, at a temperature ranging between 0°C and room temperature, for 30 minutes to 6 hours.
  • a reducing agent such as for instance, sodium cyanoborohydride, sodium triacetoxyborohydryde, or tetramethylamonium triacetoxyborohydride
  • an acid or basic catalyst such as for instance acetic acid, trifluoroacetic acid, zinc chloride, titanium(IV) chloride or TEA, DIPEA in a suitable solvent such as t
  • a compound of formula (I) wherein a primary or secondary amino group is present is transformed into the corresponding secondary or tertiary amino derivative.
  • the reaction is carried out with an aldehyde of formula R'CHO (XXXIII), under reductive amination conditions, preferably with reducing agent, such as for instance, sodium cyanoborohydride, sodium triacetoxyborohydryde, or tetramethylamonium triacetoxyborohydride in presence of acid or basic catalyst, such as for instance acetic acid, trifluoroacetic acid, zinc chloride, titanium(IV) chloride or TEA, DIPEA, in a suitable solvent such as tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, or mixtures thereof, at a temperature ranging between 0°C and room temperature, for 30 minutes to 6 hours.
  • reducing agent such as for instance, sodium cyanoborohydride, sodium triacetoxyborohydryde, or te
  • W is an halogen such as chloride
  • the reaction is performed in a suitable solvent such as for instance, dichloromethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, or N,N-dimethylformamide or the like at a temperature ranging from about -10°C to reflux and for a suitable time, for instance from about 30 minutes to about 96 hours.
  • a suitable solvent such as for instance, dichloromethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, or N,N-dimethylformamide or the like
  • the reaction is carried out in the presence of an opportune proton scavenger such as triethylamine, N,N-diisopropylethylamine or pyridine.
  • the reaction is carried out in the presence of a coupling agent such as, for instance, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), 1,3-dicyclohexylcarbodiimide, 1,3-diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, N-cyclohexylcarbodiimide-N'-propylmethyl polystyrene or N-cyclohexylcarbodiimide-N'-methyl polystyrene, in a suitable solvent such as, for instance, dichloromethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, N,N-dimethylformamide at a temperature ranging from about -10°C to reflux and for a suitable time, for instance
  • a coupling agent such
  • T is an halogen such as chloride
  • the reaction is performed in a suitable solvent such as for instance, dichloromethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, or N,N-dimethylformamide or the like at a temperature ranging from about - 10°C to reflux and for a suitable time, for instance from about 30 minutes to about 96 hours.
  • a suitable solvent such as for instance, dichloromethane, tetrahydrofuran, 1,4-dioxane, acetonitrile, or N,N-dimethylformamide or the like
  • the reaction is carried out in the presence of an opportune proton scavenger such as triethylamine, N,N-diisopropylethylamine or pyridine.
  • this same reaction is also carried out, with an anhydride of formula R6-OCO-T (XXXVI) wherein T is a leaving group such as -0C(O)OR6, in the presence of a tertiary amine such as TEA, DIPEA, or pyridine, in a suitable solvent such as, for instance toluene, DCM, THF, DMF and the like, at a room temperature.
  • T is a leaving group such as -0C(O)OR6
  • a tertiary amine such as TEA, DIPEA, or pyridine
  • the reaction is preferably carried out in as suitable solvent such as dichloromethane, tetrahydrofuran or the like, at a temperature ranging from about 20°C to reflux and for a time varying from about 30 minutes to about 48 hours.
  • a compound of formula (I) wherein a primary or secondary amino group is present is transformed into the corresponding guanidine derivative by reaction with a compound of formula R7N(R8)C(NH)T (XXXVIII) wherein R7 and R8 are as defined above and T is a suitable leaving group such as -S-Me, -N-S(O) 2 CF 3 , or 1H-pyrazolyl.
  • this reaction may be carried out under basic conditions, for instance in the presence of triethylamine, or potassium carbonate, in a suitable solvent such as methanol, ethanol, N,N-dimethylformamide, and a mixtures thereof.
  • the reaction is carried out at a temperature ranging from room temperature to about 80°C and for a time varying from about 30 minutes to about 24 hours.
  • a compound of formula (I) wherein a primary or secondary amino group is present is converted into a compound of formula (I) wherein is present a group of formula -NS(O) 2 R9, wherein R9 is as defined above.
  • the said convertion is obtained by reaction with sulfonyl compounds such as sulfonyl halides, preferably chloro or bromo, in a suitable solvent, such as DCM, at a temperature between about RT to about the reflux temperature of the solvent, in the presence of a suitable base, such as TEA, DIEA, DMAP.
  • a suitable solvent such as DCM
  • the deprotection of the nitrogen atom of a compound of formula (I) wherein R' is a protecting group can be accomplished according to conventional methods enabling the selective hydrolysis of tert -butoxycarbonyl, benzyl, 4-methoxybenzyl, 2,4-dimethoxybenzyl, and triphenylmethyl protective groups.
  • this reaction is run under acidic conditions, for instance in the presence of an inorganic or organic acid such as hydrochloric, trifluoroacetic or methansulfonic acid, in a suitable solvent such as DCM, 1,4-dioxane, a lower alcohol, such as methanol or ethanol, at a temperature ranging from room temperature to reflux and for a period of time ranging from about 1 hour to about 48 hours.
  • an inorganic or organic acid such as hydrochloric, trifluoroacetic or methansulfonic acid
  • a suitable solvent such as DCM, 1,4-dioxane, a lower alcohol, such as methanol or ethanol
  • the starting materials and any other reactants are known or easily prepared according to known methods.
  • the compounds of the formula (II) and (XXVII) can be prepared as described in WO2010/031816 .
  • racemate resolution includes, for instance, partitioned crystallization of diastereoisomeric salt derivatives or preparative chiral HPLC.
  • the compounds of the present invention can be administered either as single agents or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents (e.g.
  • cytostatic or cytotoxic agents antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), matrixmetalloprotease inhibitors, telomerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor agents, anti
  • angiogenesis inhibitors farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.
  • such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within the approved dosage range.
  • the compounds of the formula (I) of the present invention suitable for administration to a mammal, e.g., to humans, can be administered by the usual routes and the dosage level depends upon the age, weight, conditions of the patient and administration route.
  • the present invention also includes pharmaceutical compositions comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient, which may be a carrier or a diluent.
  • a pharmaceutically acceptable excipient which may be a carrier or a diluent.
  • the liquid dispersions for oral administration may be, e.g., syrups, emulsions and suspensions.
  • the syrups may contain, as carrier, saccharose or saccharose with glycerine and/or mannitol and sorbitol.
  • the suspensions and the emulsions may contain, as examples of carriers, natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., sterile water, olive oil, ethyl oleate, glycols, e.g., propylene glycol and, if desired, a suitable amount of lidocaine hydrochloride.
  • the solutions for intravenous injections or infusions may contain, as a carrier, sterile water or preferably they may be in the form of sterile, aqueous, isotonic, saline solutions or they may contain propylene glycol as a carrier.
  • the suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
  • a pharmaceutically acceptable carrier e.g., cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
  • the HPLC equipment consisted of a Waters AcquityTM UPLC system equipped with a Waters 2996 PDA detector, a Waters Acquity ELSDTM detector and Waters mod. SQD single quadrupole mass spectrometer, equipped with an electrospray (ESI) ion source. Instrument control, data acquisition and data processing were provided by Empower 2 and MassLynx 4.1 softwares.
  • HPLC HPLC was carried out at 45°C at a flow rate of 0.7 mL/min using a Waters AcquityTM BEH C18, 1.7 ⁇ m, 50 x 2.1 mm column.
  • Mobile phase A was 0.1% trifluoro acetic acid in water/acetonitrile (95:5), and mobile phase B was H 2 O/acetonitrile (5:95); the gradient was from 5 to 95% B in 2 minutes then hold 95% B 0.1 minutes.
  • the injection volume was 0.8 ⁇ L.
  • the mass spectrometer was operated in positive and in negative ion mode, the capillary voltage was set up at 3 KV (ES + and ES - ); cone was 30 V (ES + and ES - ); the source temperature was 120°C; full scan, mass range from 100 to 800 amu was set up.
  • HPLC-MS analyses were performed on a Finnigan MAT mod.
  • LCQ ion trap mass spectrometer equipped with an ESI (Electrospray) ion source, the mass spectrometer is directly connected to a HPLC SSP4000 (Thermo Separation) equipped with an autosampler Lc Pal (CTC Analytics) and an UV6000LP PDA detector.
  • HPLC HPLC was carried out at 40°C at a flow rate of 1.0 mL/min using a Phenomenex Gemini C18, 3 ⁇ m, 50 x 4.6 mm column.
  • Mobile phase A was Acetate Buffer 5 mM pH 4.5: acetonitrile 95:5 (v:v)
  • mobile phase B was Acetate Buffer 5 mM pH 4.5 : acetonitrile 5:95 (v:v) the gradient was from 0 to 100% B in 7 minutes then hold 100% B for 2 minutes before requilibration.
  • Total LC time was 10 minutes.
  • the injection volume was 10 ⁇ l.
  • MS conditions the LCQ mass spectrometer operates with an electrospray ionization (ESI) interface in positive and negative ion mode.
  • ESI sprayer voltage 4.0 kV
  • heated capillary temperature 255°C heated capillary temperature 255°C
  • sheath gas nitrogen with a pressure of 5.0 Bar.
  • a full scan detection mode (from 50 to 1000 amu) was used.
  • MS/MS experiments were performed on the most intense ion of each scan automatically by Excalibur software. 45 % collision energy was used for the fragmentation of the precursor ions.
  • the injection volume was 10 ⁇ L.
  • the mass spectrometer was operated in positive and in negative ion mode, the capillary voltage was set up at 3.5 kV (ES + ) and 2.8 kV (ES - ); cone voltage was 14 V (ES + ) and 28 V (ES - ); the source temperature was 120°C; full scan, mass range from 100 to 800 amu was set up.
  • HPLC HPLC
  • HT 2795 Waters AllianceTM HT 2795 system equipped with a Waters 2996 PDA detector and Waters mod.
  • ZQ 2000 single quadrupole mass spectrometer equipped with an electrospray (ESI) ion source.
  • Instrument control, data acquisition and data processing were provided by Empower 2 and MassLynx 4.1 softwares.
  • HPLC was carried out at 25°C at a flow rate of 1.2 mL/min using a Waters X-Terra RP18, 3.5 ⁇ m, 20 x 3.0 mm column.
  • the injection volume was 10 ⁇ L.
  • the mass spectrometer was operated in positive and in negative ion mode, the capillary voltage was set up at 3.5 kV (ES + ) and 2.8 kV (ES - ); cone voltage was 14 V (ES + ) and 28 V (ES - ); the source temperature was 120°C; full scan, mass range from 100 to 800 amu was set up.
  • the liquid chromatograph was equipped with a 30 ⁇ 3.0 mm I.D. column (Waters xBridge C18, 3.5 um particles), thermostated at 50 °C.
  • phase A was 0.05% w/v formic acid (1 mL/L of 50% formic acid Fluka 09676 in highly purified water) and phase B was 70/25/5 (v/v/v) MeOH/iPrOH/H2O containing 0.035% w/v of formic acid (700 uL/L of 50% formic acid Fluka 09676).
  • the UV detector was operated at 220 nm, 5 Hz sampling rate.
  • the MS device was operated at 3.2 kV capillary voltage, 30 V cone, 2 V extractor, 0.5 V RF lens, 400 L/hr desolvation flow, 100 L/hr cone flow, 100 °C source temperature, 150 °C desolvation temperature, ESI(+) full scan 120-1200 amu acquisition, at 1.7 Hz sampling rate.
  • the CLND detector was operated at 1050 °C furnace temp, 280 mL/min inlet oxygen flow, 80 mL/min inlet argon, 25 mL/min make-up argon, 30 mL/min ozone, 28 torr vacuum, 750 V PMT voltage, PMT chamber at +10 °C, sensitivity high, select 5, 4 Hz sampling rate.
  • the HPLC equipment consisted of a Waters FractionLynxTM system equipped with a Waters 2996 PDA detector and Waters mod. ZQ 2000 single quadrupole mass spectrometer, equipped with an electrospray (ESI) ion source. Instrument control, data acquisition and data processing were provided by MassLynx 4.1 software.
  • HPLC HPLC was carried out at 25°C at a flow rate of 20 mL/min using a Waters X-Terra Prep RP18, 10 ⁇ m, 250 x 19 mm column.
  • Mobile phase A was 0.1% trifluoro acetic acid in water/acetonitrile (95:5), and mobile phase B was acetonitrile; the gradient was from 10 to 90% B in 15 minutes then c.
  • the injection volume was 500 ⁇ L.
  • the mass spectrometer was operated in positive and in negative ion mode, the capillary voltage was set up at 3.25 kV (ES + ) and 2.75 kV (ES - ); cone voltage was 18 V (ES + ) and 25 V (ES - ); the source temperature was 120°C; full scan, mass range from 100 to 800 amu was set up.
  • the HPLC equipment consisted of a Shimadzu HPLC system equipped with SCL-8A System Controller, two LC-8A Pumps, SPD-6A UV Spectrophotometric Detector and manual Rheodyne injection system. Data acquisition (analogic signal) and data processing were provided by Empower 2 software.
  • HPLC HPLC was carried out at 25°C at a flow rate of 40 mL/min using a Waters X-Terra MS RP18, 10 ⁇ m, 150 x 30 mm column.
  • Mobile phase A was 0.1% trifluoro acetic acid in water/acetonitrile (95:5), and mobile phase B was H 2 O/acetonitrile (5:95); the gradient was from 10 to 90% B in 15 minutes then ramp to 100% B in 0.1 minutes.
  • the injection volume was 500 ⁇ L.
  • the reaction mixture was capped under argon atmosphere and stirred at 80° for 2 h.
  • the solvent was evaporated under vacuum and the residue partitioned between ethyl acetate and water.
  • the organic phase was dried on Na 2 SO 4 and concentrated to dryness.
  • the crude was purified by chromatography on a silica gel column (eluent: DCM /EtOAc/EtOH: 60/35/5) to afford 0.573 g (60 % yield) as a light brown solid.
  • Step b 71 mg (0.206 mmol) of ⁇ [7-(3-chlorophenyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl]methyl ⁇ carbamic azide were dissolved in 10 ml of dry THF, NaOH 1N (2 ml) was added and the mixture was stirred at room temperature for 30 minutes. The reaction was diluted with EtOAc and extracted with water, the organic layer was mixed with HCI 2N (5 ml) for 10 minutes, and then discarded; the aqueous solution was brought to pH 10 with NaOH 23% (10 ml) and portioned between EtOAc (10 ml) and THF (10 ml).
  • Acetic acid (2.5 ml) and sodium acetate (32.5 mmol, 2.6 g) were added to a solution of dimethyl L-aspartate hydrochloride (29.5 mmol, 5.830 g) in dichloromethane (60 ml) and water (30 ml).
  • Tetrahydro-2,5-dimethoxyfuran (29.5 mmol, 3.8 ml) was added to the resulting mixture heated at 80 °C. After 90 min. the solution was cooled and the acqueous layer was washed with DCM. The combined organic layers were washed with brine and then dried, filtered and evaporated.
  • tert -butyl 4-formylpiperidine-1-carboxylate (1.2 g, 5.6 mmol) and nitromethane (0.61 mL, 11.2 mmol) were added to a solution of THF (15 ml) and t-BuOH (15 ml) and addition of K-OtBu (0.63 g, 5.6 mmol) followed. The mixture was stirred at room temperature for 2 h. The reaction mixture was brought to pH 6 using HOAc, diluted with EtOAc (30 mL), and extracted with brine. The aqueous layer was extracted with EtOAc (30 mL x 2) The combined organic layers were washed with brine, dried, and concentrated to dryness.
  • tert -butyl 4- ⁇ 2-[(2,4-dimethoxybenzyl)amino]-1-hydroxyethyl ⁇ piperidine-1-carboxylate (0.4 g, 1.01 mmol) was added to a solution of 1-(4-acetyl-1 H -pyrrol-2-yl)-2,2,2-trichloroethanone (0.336 mg, 1.01 mmol) and N,N- diisopropylethylamine (DIPEA) (0.9 mL, 5 mmol) in dioxane (10 mL) and the reaction mixture was stirred at 100°C for 6 hours.
  • DIPEA N,N- diisopropylethylamine
  • Step b 2- ⁇ 1-oxo-7-[3-(trifluoromethoxy)phenyl]-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl ⁇ ethyl methanesulfonate (150 mg, 0.36 mmol) were reacted with sodium azide (60 mg 0.924 mmol) in acetonitrile/DMF 10 ml/2 ml at 80°C for 18 hours. The reaction was worked up with water, saturated NaHCO 3 and extracted with ethyl acetate. The organic phase, dried on Na 2 SO 4 , was filtered and evaporated.
  • the mixture was heated at 80° for 1 hour in a sealed vial.
  • the reaction was filtered through a celite pad and the solvent evaporated to dryness.
  • the crude was then portioned between ethyl acetate and water, the organic layer dried over sodium sulphate and the solvent removed in vacuo.
  • Lithium hydroxyde (0.022 g, 0.52 mmol) was added to a a solution of methyl 4- ⁇ 4-(2-chloroethyl)-1-oxo-7-[3-(trifluoromethoxy)phenyl]-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl ⁇ benzoate (0.130 g, 0.26 mmol) in THF-water (1:1, 4 ml) and the reaction mixture was stirred at room temperature for 12h. The solvent (THF) was removed under reduced pressure and the aqueous residue was diluted with water.
  • Ammonium chloride (0.025 g, 0.48 mmol) was added to a solution of 4- ⁇ 4-(2-chloroethyl)-1-oxo-7-[3-(trifluoromethoxy)phenyl]-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl ⁇ benzoic acid (0.040 g, 0.080 mmol), DIPEA (0.062 g, 0.48 mmol) and TBTU (0.040 g, 0.125 mmol) in DMF (2 ml). The reaction mixture was stirred at room temperature for 12 hours, concentrated to dryness and the residue was dissolved with DCM and washed with water.
  • Lithium hydroxyde (0.053 g, 1.26 mmol) was added to a a solution of methyl 4- ⁇ 4-(2-hydroxyethyl)-1-oxo-7-[3-(trifluoromethoxy)phenyl]-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl ⁇ benzoate (0.200 g, 0.42 mmol) in THF-water (1:1, 4 ml) and the reaction mixture was stirred at room temperature for 12h. The THF was removed under reduced pressure and the aqueous residue was diluted with water.
  • Ammonium chloride (0.027 g, 0.52 mmol) was added to a solution of 4- ⁇ 4-(2-hydroxyethyl)-1-oxo-7-[3-(trifluoromethoxy)phenyl]-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl ⁇ benzoic acid (0.040 g, 0.087 mmol), DIPEA (0.067 g, 0.52 mmol) and TBTU (0.042 g, 0.13 mmol) in DMF (2 ml). The reaction mixture was stirred at room temperature for 12 hours, concentrated to dryness and the residue was taken into DCM and washed with water.
  • the mixture was heated at 80° for 1 hour in a sealed vial.
  • the reaction was filtered through a celite pad and the solvent evaporated to dryness.
  • the crude was then portioned between ethyl acetate and water, the organic layer dried over sodium sulphate and the solvent removed in vacuo.
  • N,N-dimethyl-4-( ⁇ (4S)-1-oxo-7-[3-(trifluoromethoxy)phenyl]-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-4-yl ⁇ methyl)-1H-imidazole-1-sulfonamide was dissolved in a mixture 1:1 of water (2ml) and 4N HCl in dioxane (2 ml) and heated at 75°C until deprotection was completed. After evaporation under vacuo, purification by RP-HPLC afforded the title compound as a white solid.
  • 1 H NMR 600 MHz, DMSO-d6) ⁇ 9.00 (br.
  • the compounds of formula (I) are active as protein kinase inhibitors and are therefore useful, for instance, to restrict the unregulated proliferation of tumour cells.
  • tumours such as those formerly defined, as well as in the treatment of other cell proliferative disorders such as benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
  • other cell proliferative disorders such as benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
  • the inhibitory activity of putative kinase inhibitors and the potency of selected compounds were determined using a trans-phosphorylation assay.
  • Specific peptide or protein substrates were trans-phosphorylated by their specific ser-thr or tyr kinase in the presence of ATP traced with 33 P- ⁇ -ATP, and in the presence of their own optimal buffer and cofactors.
  • the resin was allowed to settle down (some hours) and then the supernatant was discarded.
  • the resin was allowed to settle and two volumes (wrt the resin volume) of 150 mM sodium formate buffer were added.
  • the washed resin was stable for more than one week; the stock resin was kept at 4° C before use.
  • the buffer for PIM1 assay was composed of HEPES 50 mM, at pH 7.5, with 10 mM MgCl 2 , 1 mM DTT, 3 ⁇ M NaVO 3 , and 0.2 mg/mL BSA.
  • the enzyme showed a linear kinetic after a step of pre-activation by auto-phosphorylation in the following conditions: 1.7 ⁇ M PIM1 was incubated 1 h at 28° C in the presence of 125 ⁇ M ATP.
  • the test mix consisted of:
  • test compounds were received as a 1 mM solution in 100% DMSO and distributed into 96-well plates: compounds were then plated into the first column of a new 96-well plate (A1 to G1), 100 ⁇ l/well.
  • Each 384-well plate generated at least one curve of the standard inhibitor staurosporine and reference wells (total enzyme activity vs. no enzymatic activity) for evaluation of Z' and signal to background (S/B) ratio.
  • 384-well plates, V bottom (test plates) were prepared with 5 ⁇ l of compound diluted as previously described (3X) and then placed onto a PlateTrak 12 robotized station (Perkin Elmer; the robot has one 384-tip pipetting head for assay start, plus one 96-tip head for dispensing resin) together with one reservoir for Enzyme mix (3X) and one for ATP mix (3X).
  • the buffer for PIM2 assay was composed of HEPES 50 mM, at pH 7.5, with 1 mM MgCl2, 1 mM DTT, 3 ⁇ M Na 3 VO 4 , and 0.2 mg/mL BSA.
  • Full-length human PIM2 was expressed and purified as described in Fedorov O, et al., PNAS 2007 104, 51, 20523-28 .
  • BaF3 cell line transfected with PIM1 was generated following the procedure described in Pogacic, V. et al Cancer Research 2007, 67, 6916-6924 .
  • MV-4-11 (biphenotypic B myelomonocytic leukemia) cell line was obtained from ATCC.
  • Media for BaF3-PIM1 cell line contained RPMI 1640 plus 2mM Glutamine and 10% Fetal bovine serum.
  • Media for MV-4-11 cell line contained RPMI 1640 or EMEM plus 2 mM Glutamine and 10% Fetal bovine serum.
  • BaF3-PIM1 and MV-4-11 cells were seeded at 125 cells/well and 1250 cells/well respectively in a 384-well white plates in complete medium and treated with compounds dissolved in 0.1% DMSO, 24h after seeding.
  • the cells were incubated at 37°C and 5 % CO 2 and after 72 hours the plates were processed using CellTiter-Glo assay (Promega) following the manufacturer's instruction.
  • CellTiter-Glo was a homogenous method based on the quantification of the ATP present, an indicator of metabolitically active cells. ATP was quantified using a system based on luciferase and D-luciferin resulting into light generation. The luminescent signal was proportional to the number of cells present in culture.
  • Inhibitory activity was evaluated comparing treated versus control data using Assay Explorer (MDL) program.
  • IC 50 was calculated using sigmoidal interpolation curve.
  • the compounds of the formula (I) of the invention resulted to possess a good PIM-1 inhibitory activity, tipically with an IC 50 well below 0.05 microM and a good PIM-2 inhibitory activity, tipically with an IC 50 well below 0.2 microM.
  • the compounds of the formula (I) of the invention showed good cellular proliferation inhibitory activity, tipically with an IC 50 in the range of from 1 to 7 microM in MV-4-11 and in the range of from 0.05 to 7 microM in BaF3-PIM1 cells.
  • Table A reports the experimental data of some representative compounds of the invention of formula (I) being tested in the specific in vitro kinase assay above described on the PIM-1 and PIM- 2 enzyme in comparison with some Ref. compounds of the prior art.
  • Ref. compounds are disclosed in the patent application WO2010/031816 cited above.
  • Table A Compound PIM-1 IC 50 ⁇ M PIM-2 IC 50 ⁇ M BaF3-PIM1 IC 50 ⁇ M MV4-11 IC 50 ⁇ M Ref. cmp 1 (A157-M-B65 isomer S) 0.01 0.10 >10 Ref. cmp 2 (A127-M-B65 isomer S) 0.01 0.18 >10 Ref.
  • cmp 3 (A127-M-B61 isomer S) 0.02 0.25 >10 28 0.007 0.055 0.275 1.736 29 0.019 0.143 0.315 2.618 55 0.017 0.077 0.140 3.605 57 0.016 0.032 0.239 2.603 82 0.001 0.035 0.486 5.965 83 0.004 0.038 0.329 2.888 85 0.012 0.069 0.085 3.658 87 0.009 0.038 0.202 3.613 92 0.005 0.015 0.147 2.200 17 0.034 0.117 0.450 31 0.023 0.051 0.326 2.593 32 0.008 0.069 2.025 59 0.040 0.114 0.323 4.620 33 0.004 0.015 0.598 38 0.020 0.102 3.030 40 0.043 0.155 0.340 5.036 44 0.024 0.110 6.570 45 0.041 0.102 3.960 3.170 43 0.012 0.021 7.000 77 0.007 0.058 2.325 79 0.013 0.0
  • novel compounds of the invention are unexpectedly endowed with a potent PIM-1 and PIM-2 inhibitory activity resulting in an antiproliferative activity significantly higher than that of the structurally closest prior art compounds. Therefore, the compounds of the invention are particularly advantageous, in therapy, against cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (12)

  1. Composé de formule (I) :
    Figure imgb0161
     dans laquelle
    A est un groupe - (CH2)1-3-X-R1 ;
    R1 est un atome d'hydrogène, un atome d'halogène ou un groupe sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, arylalkyle, hétérocyclyle et hétérocyclylalkyle ;
    R2 est un groupe sélectionné parmi les groupes alcynyle en C2 à C6, aryle et hétérocyclyle ;
    R3 et R4 sont chacun indépendamment un atome d'hydrogène, un atome d'halogène, un groupe cyano ou un groupe sélectionné parmi les groupes cycloalkyle en C3 à C7, cycloalkylalkyle, alcényle en C2 à C6, alcynyle en C2 à C6, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle ;
    X est une liaison simple ou un radical divalent sélectionné parmi -NR'- et -0-, où R' est un atome d'hydrogène, COR5, C(NH)R5, S(O)2R9 ou les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle, ou ensemble avec l'atome d'azote auquel ils sont liés, R' et R1 peuvent former un groupe hétéroaryle ou hétérocyclyle de 5 à 7 chaînons contenant facultativement un hétéroatome supplémentaire sélectionné parmi N, O et S ; où :
    R5 est OR6, NR7R8 ou un groupe sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, alcényle en C2 à C6, alcynyle en C2 à C6, aryle, arylalkyle, hétérocyclyle et
    hétérocyclylalkyle, où :
    R6 est un groupe sélectionnéparmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, aryle et hétérocyclyle ;
    R7 et R8 sont chacun indépendamment un atome d'hydrogène ou un groupe sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, aryle et hétérocyclyle ;
    R9 est un groupe sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, aryle et hétérocyclyle ;
    dans laquelle l'un quelconque des groupes R1 à R9 et R' ci-dessus peut être facultativement substitué, sur l'une quelconque de leurs positions libres, par 1 à 6 groupes indépendamment sélectionnés parmi : un atome d'halogène, les groupes nitro, oxo (=O), cyano, alkyle en C1 à C6, alkyle polyfluoré, alcoxypolyfluoré, alcényle, alcynyle, hydroxyalkyle, aryle, arylalkyle, hétérocyclyle, cycloalkyle en C3 à C7, hydroxy, alcoxy, aryloxy, hétérocyclyloxy, méthylènedioxy, alkylcarbonyloxy, arylcarbonyloxy, cycloalcényloxy, hétérocyclylcarbonyloxy, alkylidèneaminooxy, carboxy, alcoxycarbonyle, aryloxycarbonyle, cycloalkyloxycarbonyle, hétérocyclyloxycarbonyle, amino, uréido, alkylamino, dialkylamino, arylamino, diarylamino, hétérocyclylamino, formylamino, alkylcarbonylamino, arylcarbonylamino, hétérocyclylcarbonylamino, aminocarbonyle, alkylaminocarbonyle, dialkylaminocarbonyle, arylaminocarbonyle, hétérocyclylaminocarbonyle, alcoxycarbonylamino, hydroxyaminocarbonylealcoxyimino, alkylsulfonylamino, arylsulfonylamino, hétérocyclylsulfonylamino, formyle, alkylcarbonyle, arylcarbonyle, cycloalkylcarbonyle, hétérocyclylcarbonyle, alkylsulfonyle, arylsulfonyle, aminosulfonyle, alkylaminosulfonyle, dialkylaminosulfonyle, arylaminosulfonyle, hétérocyclylaminosulfonyle, arylthio, alkylthio, phosphonate et alkylphosphonate ;
    ou un sel pharmaceutiquement acceptable de celui-ci.
  2. Composé de formule (I) tel que défini selon la revendication 1, dans lequel :
    A est - (CH2)1-3-X-R1 où X est -NR'- ; R' est COR5 ; R5 est NR7R8 ou un groupe facultativement substitué sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, alcényle en C2 à C6, alcynyle en C2 à C6, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle, où R7 et R8 sont tels que définis dans la revendication 1.
  3. Composé de formule (I) tel que défini selon les revendications 1 à 2, dans lequel :
    A est - (CH2)1-3-X-R1 où X est -NR'- ; R' est COR5 ; R5 est NR7R8 ou un groupe facultativement substitué sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle, où R7 et R8 sont chacun indépendamment un atome d'hydrogène ou un groupe facultativement substitué sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, aryle et hétérocyclyle ; et
    R4 est un atome d'hydrogène, un atome d'halogène, un groupe cyano ou un groupe facultativement substitué sélectionné parmi les groupes cycloalkyle en C3 à C7, cycloalkylalkyle, alcényle en C2 à C6, alcynyle en C2 à C6, aryle et, hétérocyclyle.
  4. Composé ou un sel pharmaceutique acceptable de celui-ci, qui est sélectionné dans le groupe constitué par :
    la 7-(3-chlorophényl)-4-(2-hydroxyéthyl)-6-phényl-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 2),
    la 7-(3-chlorophényl)-4-{2-[(1-méthylpipéridin-4-yl)amino]éthyl}-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 5),
    la (4S)-7-(3-chlorophényl)-4-(2-{[(1S)-1-cyclohexyl-2-(4-méthylpipérazin-1-yl)éthyl]amino}éthyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 8),
    la 7-(biphényl-2-yl)-4-{2-[(1-méthylpipéridin-4-yl)amino]éthyl}-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 12),
    la 7-(3-chlorophényl)-4-{2-[(1-méthylpipéridin-4-yl)amino]éthyl}-6-phényl-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 13),
    la 4-(2-aminoéthyl)-7-(3-chlorophényl)-6-phényl-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 17),
    la 4-(2-aminoéthyl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 18),
    la 4-(2-aminoéthyl)-6-bromo-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 27),
    la 4-(2-aminoéthyl)-6-phényl-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 28),
    la 4-(2-aminoéthyl)-6-(thiophén-3-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 29),
    la 4-(2-aminoéthyl)-6-(3-méthylphényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 31),
    la 4-(2-aminoéthyl)-6-[4-(hydroxyméthyl)phényl]-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 33),
    la 4-(2-aminoéthyl)-6-phényl-7-[3-(trifluorométhyl)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 37),
    la 4-(2-aminoéthyl)-6-[4-(hydroxyméthyl)phényl]-7-[3-(trifluorométhyl)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 38),
    la 4-(2-aminoéthyl)-6-(3-méthylphényl)-7-[3-(trifluorométhyl)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 39),
    la 4-(2-aminoéthyl)-6-(thiophén-3-yl)-7-[3-(trifluorométhyl)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp40),
    la 4-(2-aminoéthyl)-6-(4-hydroxyphényl)-7-[3-(trifluorométhyl)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 43),
    la 4-(2-aminoéthyl)-7-(2-chloropyridin-4-yl)-6-[4-(hydroxyméthyl)phényl]-3, 4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp44),
    la 4-(2-aminoéthyl)-7-(2-chloropyridin-4-yl)-6-(3-méthylphényl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 45),
    la 4-(2-aminoéthyl)-7-(2-fluoropyridin-4-yl)-6-(3-méthylphényl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 47),
    la 4-(2-aminoéthyl)-7-(6-fluoropyridin-3-yl)-6-phényl-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 48),
    la 4-(2-aminoéthyl)-7-(3,4-difluorophényl)-6-(3-méthylphényl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one(comp49),
    la 4-(2-aminoéthyl)-7-(3,4-difluorophényl)-6-(thiophén-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 51),
    la 4-(2-aminoéthyl)-7-(3,4-difluorophényl)-6-phényl-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 52),
    la 4-(2-aminoéthyl)-7-[2-chloro-5-(trifluorométhoxy)phényl]-6-(3-méthylphényl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 53),
    la 4-(2-aminoéthyl)-6-cyclopropyl-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 54),
    la 4-(2-aminoéthyl)-7-(5-chloro-2-fluorophényl)-6-(thiophén-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 55),
    la 4-(2-aminoéthyl)-7-(5-chloro-2-fluorophényl)-6-phényl-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 57),
    la 4-(2-aminoéthyl)-7-(5-chloro-2-fluorophényl)-6-(3-méthylphényl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 59),
    la 4-(2-aminoéthyl)-6-éthynyl-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 61),
    la 4-(2-chloroéthyl)-6-(3-méthylphényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 63),
    le 4-{4-(2-chloroéthyl)-1-oxo-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-6-yl}benzamide (comp 68),
    la 4-(2-chloroéthyl)-6-{4-[(diméthylamino)méthyl]phényl}-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 70),
    la 4-(2-chloroéthyl)-6-{4-[(4-méthylpipérazin-1-yl)méthyl]phényl}-7-[3-(trifluorométhoxy)phényl]-3,4dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 71),
    le 4-{4-(2-hydroxyéthyl)-1-oxo-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-6-yl}benzamide (comp 77),
    le N-[2-(diméthylamino)éthyl]-4-{4-(2-hydroxyéthyl)-1-oxo-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-6-yl}benzamide (comp 78),
    le 4-{4-(2-hydroxyéthyl)-1-oxo-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-6-yl}-N,N-diméthylbenzamide (comp 79),
    le 4-{4-(2-hydroxyéthyl)-1-oxo-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-6-yl}-N-méthylbenzamide (comp 80),
    le 4-{4-(2-hydroxyéthyl)-1-oxo-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-6-yl}-N-(1-méthylpipéridin-4-yl)benzamide (comp 81),
    la 6-{4-[(diméthylamino)méthyl]phényl}-4-(2-hydroxyéthyl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 83),
    la 4-(2-hydroxyéthyl)-6-[4-(hydroxyméthyl)phényl]-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 84),
    la (4S)-4-(2-aminoéthyl)-6-(thiophén-3-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp85),
    la (4R)-4-(2-aminoéthyl)-6-(thiophén-3-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp86),
    la (4S)-4-(2-aminoéthyl)-6-phényl-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 87),
    la (4R)-4-(2-aminoéthyl)-6-phényl-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 88),
    la (4S)-4-(2-aminoéthyl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp89),
    la (4S)-4-(3-aminopropyl)-7-[3-(tnfluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 90),
    la (4S)-4-(2-aminoéthyl)-6-(3-méthylphényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 92),
    la (4S)-4-(2-aminoéthyl)-6-(4-fluorophényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 94),
    la (4S)-6-(4-acétylphényl)-4-(2-aminoéthyl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 95),
    la (4S)-4-(2-aminoéthyl)-6-[4-(méthylsulfonyl)phényl]-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one, (comp 96),
    la (4S)-4-(2-aminoéthyl)-6-[4-(morpholin-4-ylméthyl)phényl]-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 99),
    la (4S)-4-(2-aminoéthyl)-6-{4-[(4-méthylpipérazin-1-yl)méthyl]phényl}-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one(comp 100),
    la (4S)-4-(2-aminoéthyl)-6-{4-[(diméthylamino)méthyl]phényl}-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one, (comp 101),
    la (4S)-4-(3-aminopropyl)-6-phényl-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 102),
    la (4S)-4-(3-aminopropyl)-6-(thiophén-3-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 103),
    la (4S)-4-(3-aminopropyl)-6-(4-hydroxyphényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 104),
    la (4S)-(3-aminopropyl)-6-[4-(hydroxyméthyl)phényl]-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 105),
    la (4S)-4-(2-chloroéthyl)-6-{4-[(4-méthylpipérazin-1-yl)méthyl]phényl}-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 106),
    la (4S)-4-(1H-imidazol-4-ylméthyl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 107),
    la (4S)-6-(4-acétylphényl)-4-(3-aminopropyl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 110),
    la (4S)-4-(3-aminopropyl)-6-(4-fluorophényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 111),
    la (4S)-4-(2-aminoéthyl)-6-(1,3-benzodioxol-5-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 112),
    la (4S)-4-(2-aminoéthyl)-6-(3-fluoro-4-méthoxyphényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 113),
    la (4S)-4-(2-aminoéthyl)-6-[4-(2-méthylpropoxy)phényl]-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 114),
    la (4S)-4-(2-aminoéthyl)-6-[4-(diméthylamino)phényl]-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 115),
    la (4S)-(2-aminoéthyl)-6-(4-méthoxyphényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 116),
    la (4S)-4-(2-aminoéthyl)-6-(2-aminopyrimidin-5-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 117),
    la (4S)-4-(2-aminoéthyl)-6-(naphtalén-2-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 118),
    la (4S)-4-(2-aminoéthyl)-6-(biphényl-3-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 119),
    le 4-{(4S)-4-(2-aminoéthyl)-1-oxo-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-6-yl}benzènesulfonamide(comp 120),
    la (4S)-4-(2-aminoéthyl)-6-(3-fluorophényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 121),
    la (4S)-4-(2-aminoéthyl)-6-(4-fluoro-3-méthylphényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 122),
    la (4S)-4-(2-aminoéthyl)-6-[4-(méthylsulfanyl)phényl]-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 123),
    la (4S)-4-(2-aminoéthyl)-6-(4-tert-butylphényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 124),
    la (4S)-4-(2-aminoéthyl)-7-[3-(trifluorométhoxy)phényl]-6-[3-(trifluorométhyl)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 125),
    la (4S)-4-(2-aminoéthyl)-6-(3-chlorophényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 126),
    la (4S)-4-(2-aminoéthyl)-6-(4-éthoxy-3-fluorophényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 127),
    la (4S)-4-(2-aminoéthyl)-6-(4-méthoxy-3,5-diméthylphényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 128),
    la (4S)-4-(2-aminoéthyl)-6-(3-chloro-4-méthoxyphényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 129),
    la (4S)-6-[4-(1-aminocyclopropyl)phényl]-4-(2-aminoéthyl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 130),
    la (4S)-6-[4-(1-aminocyclopropyl)phényl]-4-(propan-2-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 131),
    la (4S)-6-(4-éthoxy-3-fluorophényl)-4-(1H-imidazol-4-ylméthyl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 132),
    la (4S)-4-(1H-imidazol-4-ylméthyl)-6-(3-méthylphényl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 133),
    la (4S)-4-(3-aminopropyl)-6-{4-[(diméthylamino)méthyl]phényl}-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 134),
    la (4S)-4-(3-aminopropyl)-6-{4-[(4-méthylpipérazin-1-yl)méthyl]phényl}-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 135),
    la (4S)-6-{4-[(diméthylamino)méthyl]phényl}-4-(propan-2-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 136),
    la (4S)-6-{4-[(4-méthylpipérazin-1-yl)méthyl]phényl}-4-(propan-2-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 137),
    la (4S)-6-[4-(aminométhyl)phényl]-4-(propan-2-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 138),
    la (4S)-6-[3-(diméthylamino)prop-1-yn-1-yl]-4-(propan-2-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 139),
    la (4S)-6-(3-aminoprop-1-yn-1-yl)-4-(propan-2-yl)-7-[3-(trifluorométhoxy)phényl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (comp 140),
    le 2,2-diméthyl-N-(2-{(4S)-6-(3-méthylphényl)-1-oxo-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-4-yl}éthyl)propanamide (comp 141),
    le N-(2-{(4S)-1-oxo-6-phényl-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-4-yl}éthyl)acétamide (comp 142),
    le 2,2-diméthyl-N-(2-{(4S)-1-oxo-6-phényl-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-4-yl}éthyl)propanamide (comp 143),
    la 1-tert-butyl-3-(2-{(4S)-6-(3-méthylphényl)-1-oxo-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-4-yl}éthyl)urée (comp 144),
    la 1-tert-butyl-3-(2-{(4S)-1-oxo-6-phényl-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-4-yl}éthyl)urée (comp 145),
    la 1-butan-2-yl-3-(2-{(4S)-1-oxo-6-phényl-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-4-yl}éthyl)urée (comp 146),
    le N-(2-{(4S)-1-oxo-6-phényl-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-4-yl}éthyl)méthanesulfonamide (comp 147),
    la 1-(2-{(4S)-6-(3-méthylphényl)-1-oxo-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-4-yl}éthyl)guanidine (comp 148), et
    la 1-(2-{(4S)-6-[4-(méthylsulfonyl)phényl]-1-oxo-7-[3-(trifluorométhoxy)phényl]-1,2,3,4-tétrahydropyrrolo[1,2-a]pyrazin-4-yl}éthyl)guanidine (comp 149).
  5. Procédé de préparation d'un composé de formule(I) tel que défini selon la revendication1 ou d'un composé tel que défini selon la revendication4 ou de sels pharmaceutiquement acceptables de ceux-ci, caractérisé en ce que le procédé comprend l'étape suivante :
    étape 5) faire réagir un composé de formule (VI)
    Figure imgb0162
     dans laquelle R' est un atome d'hydrogène ou un groupe protecteur et R1 est tel que défini selon la revendication 1, selon l'une quelconque des étapes alternatives :
    étape 5a) avec un organobore de formule (XII) :

            R2'B(OZ')OZ''     (XII)

    dans laquelle R2' est un groupe facultativement substitué sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, alcényle en C2 à C6, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle ;
    et Z' et Z'' sont un atome d'hydrogène ou un groupe alkyle en C1 à C6 ou ensemble avec les atomes d'oxygène auxquels ils sont attachés, peuvent former un hétérocycle de 5 à 6 chaînons facultativement substitué,
    ou
    étape 5b) avec un alcyne terminal de formule (XIII) :

            RaC≡CH     (XIII)

    dans laquelle Ra est un atome d'hydrogène ou un groupe facultativement substitué sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, alcényle en C2 à C6, alcynyle en C2 à C6, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle ;
    ou
    étape 5') d'abord avec un réactif boronyle ;
    étape 5") ensuite mélanger le composé résultant de formule (VIa)
    Figure imgb0163
     dans laquelle R1, R', Z' et Z" sont tels que définis ci-dessus, avec un composé de formule R2"-Q (XIV) dans laquelle R2" est un groupe facultativement substitué sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle et Q est un atome d'halogène ou un groupe triflate, ou un groupe alkylsulfonyloxy ou un groupe arylsulfonyloxy, tel qu'un groupe mésylate ou tosylate ;
    ou
    étape 9) mélanger un composé de formule (VII)
    Figure imgb0164
     dans laquelle R2 est un groupe facultativement substitué sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle, avec un agent de réduction ;
    ou
    étape 12) mélanger un composé de formule (X)
    Figure imgb0165
     dans laquelle R2 est un groupe aryle et R3 est un groupe facultativement substitué sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, alcényle en C2 à C6, alcynyle en C2 à C6, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle, avec un agent de réduction ;
    étape 14) faire réagir dans les conditions de la réaction de Curtius, un composé de formule (XI)
    Figure imgb0166
     dans laquelle R2 est un groupe facultativement substitué sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, alcényle en C2 à C6, alcynyle en C2 à C6, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle ; et R3 est un atome d'hydrogène ; convertir facultativement un composé de formule (I) en un composé de formule (I) différent par des réactions chimiques connues ; et/ou si souhaité, convertir un composé de formule (I) en un sel pharmaceutiquement acceptable de celui-ci ou convertir un sel en un composé de formule (I) libre.
  6. Procédé selon la revendication 5, caractérisé en ce que la conversion d'un composé de formule (I) en un autre composé de formule (I) différent est réalisée avec l'une des méthodes suivantes :
    conv b) convertir un composé de formule (I) dans laquelle un groupe -CH2OH est présent, en composé de formule (I) correspondantavec un groupe -CH2NR'R1
    Figure imgb0167
     dans lequel R1 est tel que défini selon la revendication 1 et R' est un atome d'hydrogène ou un groupe protecteur de formule -COOR6, dans laquelle R6 est tel que défini selon la revendication 1, par une séquence en trois étapes englobant l'activation de l'alcool, le déplacement nucléophile et la manipulation du produit post-nucléophile en une amine ;
    conv. e) convertir un composé de formule (I) dans laquelle R3 ou R4 est un atome d'hydrogène en un composé de formule (I) correspondant
    Figure imgb0168
     dans laquelle R3 ou R4 est un atome d'halogène, par le biais d'une réaction avec un agent d'halogénation ;
    conv. g) convertir un composé de formule (I) dans laquelle R3 ou R4 est un atome d'halogène en un composé de formule (I) correspondant
    Figure imgb0169
     dans laquelle R3 ou R4 est un groupe facultativement substitué sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle, par une réaction avec un composé de formule (XXXI) ou (XXXII) respectivement :
    R3''-G (XXXI) R4''-G (XXXII) dans lesquelles R3" ou R4'' est les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle et G est un groupe approprié tel que -B(OH)2, -B(OAlk)2, -Sn(OAlk)2, -Sn(Alk)4, ZnHal ou MgHal, dans des conditions de formation d'une liaison carbone médiée par du palladium ;
    conv. i) convertir un composé de formule (I) dans laquelle est présent un groupe L-COOPg, où L est un groupe facultativement substitué sélectionné parmi les groupes alkyle en C1 à C6 linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, alcényle en C2 à C6, alcynyle en C2 à C6, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle et Pg est un groupe protecteur approprié, en composé de formule (I) correspondant
    Figure imgb0170
     dans laquelle un groupe L-COOH est présent, où L est tel que défini ci-dessus ;
    conv. j) convertir un composé de formule (I) dans laquelle un groupe L-COOH est présent, où L est tel que défini ci-dessus, en composé de formule (I) correspondant
    Figure imgb0171
     dans laquelle un groupe L-CONR'R1 est présent, par traitement avec une amine de formule R1R'-NH (XXX) dans laquelle R' et R1 sont tels que définis ci-dessus, en présence des agents de condensation appropriés ;
    conv. l) convertir un composé de formule (I) dans laquelle une amine secondaire ou tertiaire est présente, en composé de formule (I) correspondant
    Figure imgb0172
     dans laquelle une amine secondaire ou tertiaire est présente, par un traitement avec un composé de formule R'-CHO (XXXIII) dans laquelle R' est un groupe facultativement substitué sélectionné parmi les groupes alkyle en C1 à C6linéaire ou ramifié, cycloalkyle en C3 à C7, cycloalkylalkyle, aryle, arylalkyle, hétérocyclyle et hétérocyclylalkyle ; conv r) éliminer n'importe quel groupe protecteur.
  7. Procédé in vitro d'inhibition d'une activité de la protéine kinase qui comprend la mise en contact de ladite protéine avec une quantité efficace d'un composé de formule (I) tel que défini selon la revendication 1 ou d'un composé tel que défini selon la revendication 4.
  8. Composition pharmaceutique comprenant une quantité thérapeutiquement efficace d'un composé de formule (I) ou d'un sel pharmaceutiquement acceptable de celui-ci, tel que défini selon la revendication 1, ou d'un composé tel que défini selon la revendication 4, et au moins un excipient, véhicule et/ou diluant pharmaceutiquement acceptable.
  9. Composition pharmaceutique selon la revendication 8, comprenant en outre un ou plusieurs agents chimiothérapeutiques.
  10. Produit ou kit comprenant un composé de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, tel que défini selon la revendication 1, ou un composé tel que défini selon la revendication 4, ou une composition pharmaceutique telle que définie selon la revendication 8 et un ou plusieurs agents chimiothérapeutiques, sous forme de préparation combinée pour une utilisation simultanée, séparée ou séquentielle dans un traitement anticancéreux.
  11. Composé de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, tel que défini selon la revendication 1, ou un composé tel que défini selon la revendication 4, pour une utilisation en tant que médicament.
  12. Composé de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, tel que défini selon la revendication 1, ou un composé tel que défini selon la revendication 4, pour une utilisation dans une méthode de traitement d'un cancer.
EP12767002.4A 2011-10-07 2012-10-04 Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitué par 4-alkyle en tant qu'inhibiteurs de kinases Active EP2788350B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12767002.4A EP2788350B1 (fr) 2011-10-07 2012-10-04 Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitué par 4-alkyle en tant qu'inhibiteurs de kinases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11184284 2011-10-07
EP12767002.4A EP2788350B1 (fr) 2011-10-07 2012-10-04 Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitué par 4-alkyle en tant qu'inhibiteurs de kinases
PCT/EP2012/069588 WO2013050448A1 (fr) 2011-10-07 2012-10-04 Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitué par 4-alkyle en tant qu'inhibiteurs de kinases

Publications (2)

Publication Number Publication Date
EP2788350A1 EP2788350A1 (fr) 2014-10-15
EP2788350B1 true EP2788350B1 (fr) 2017-12-06

Family

ID=46968234

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12767002.4A Active EP2788350B1 (fr) 2011-10-07 2012-10-04 Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitué par 4-alkyle en tant qu'inhibiteurs de kinases

Country Status (5)

Country Link
US (1) US9181258B2 (fr)
EP (1) EP2788350B1 (fr)
JP (1) JP6063945B2 (fr)
ES (1) ES2660265T3 (fr)
WO (1) WO2013050448A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
EP3036238A1 (fr) 2013-08-23 2016-06-29 Incyte Corporation Composés de furo- et thiéno-pyridinecarboxamide utiles en tant qu'inhibiteurs de kinases pim
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
CN104402776B (zh) * 2014-12-05 2017-06-13 中国石油天然气股份有限公司 一种二元醇磺酸酯化合物及其制备方法与应用
US10301306B2 (en) 2014-12-15 2019-05-28 Bristol-Myers Squibb Company Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors
CN107406417B (zh) * 2015-01-28 2020-06-09 拜耳制药股份公司 4H-吡咯并[3,2-c]吡啶-4-酮衍生物
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
CN107849046B (zh) * 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
EP3303335B1 (fr) * 2015-06-03 2021-07-28 JS Innopharm (Shanghai) Ltd. Composés hétérocycliques pour le traitement du psoriasis
DK3322706T3 (da) 2015-07-16 2021-02-01 Array Biopharma Inc Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (fr) 2015-10-02 2017-04-06 Incyte Corporation Composés hétérocycliques utiles en tant qu'inhibiteurs de la kinase pim
TW201734009A (zh) 2015-10-23 2017-10-01 艾斯提夫博士實驗股份有限公司 具有抗疼痛活性的經取代的□啉衍生物
JP2018534296A (ja) 2015-10-26 2018-11-22 ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法
RS65988B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Postupak lečenja pedijatrijskih karcinoma
MX386416B (es) 2016-04-04 2025-03-18 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE063877T2 (hu) 2016-05-18 2024-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
CA3049136C (fr) 2017-01-18 2022-06-14 Array Biopharma Inc. Composes de pyrazolo[1,5-a]pyrazine substitues utilises en tant qu'inhibiteurs de la kinase ret
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
CA3087578C (fr) 2018-01-18 2023-08-08 Array Biopharma Inc. Composes de pyrazolo[3,4-d]pyrimidine substitues utilises en tant qu'inhibiteurs de la kinase ret
WO2019143994A1 (fr) 2018-01-18 2019-07-25 Array Biopharma Inc. Composés de pyrazolyl[4,3-c]pyridine substitués utilisés en tant qu'inhibiteurs de la kinase ret
CA3087354C (fr) 2018-01-18 2023-01-03 Array Biopharma Inc. Composes de pyrrolo[2,3-d]pyrimidines substitues utilises en tant qu'inhibiteurs de la kinase ret
KR102545594B1 (ko) 2018-07-31 2023-06-21 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
EP3898626A1 (fr) 2018-12-19 2021-10-27 Array Biopharma, Inc. Composés pyrazolo[1,5-a]pyridine substitués servant d'inhibiteurs de tyrosine kinases fgfr
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
WO2021113492A1 (fr) 2019-12-06 2021-06-10 Schrödinger, Inc. Composés cycliques et leurs procédés d'utilisation
WO2021134004A1 (fr) 2019-12-27 2021-07-01 Schrodinger, Inc. Composés cycliques et leurs procédés d'utilisation
JP2023541047A (ja) 2020-09-10 2023-09-27 シュレーディンガー， インコーポレイテッド がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
US20240148732A1 (en) 2021-01-26 2024-05-09 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
WO2025059027A1 (fr) 2023-09-11 2025-03-20 Schrödinger, Inc. Dérivés de cyclopenta[e]pyrazolo[1,5-a]pyrimidine utilisés en tant qu'inhibiteurs de malt1

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
ES2536730T3 (es) * 2008-09-19 2015-05-28 Nerviano Medical Sciences S.R.L. Derivados de 3,4-dihidro-2H-pirrolo[1,2-a]pirazin-1-ona

Also Published As

Publication number Publication date
EP2788350A1 (fr) 2014-10-15
JP2014528434A (ja) 2014-10-27
US9181258B2 (en) 2015-11-10
JP6063945B2 (ja) 2017-01-18
US20140249146A1 (en) 2014-09-04
ES2660265T3 (es) 2018-03-21
WO2013050448A1 (fr) 2013-04-11

Similar Documents

Publication Publication Date Title
EP2788350B1 (fr) Dérivés 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-one substitué par 4-alkyle en tant qu'inhibiteurs de kinases
EP2788351B1 (fr) DÉRIVÉS DE LA 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE EN TANT QU'INHIBITEURS DE KINASES
EP2668188B1 (fr) Dérivés tricycliques, leur procédé de préparation et leur utilisation à titre d'inhibiteurs de kinases
TWI740135B (zh) 周期蛋白依賴性激酶抑制劑
EP2614065B1 (fr) Dérivés de pyrazolo-quinazoline substitués à titre d'inhibiteurs de kinases
JP5976778B2 (ja) キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体
JP2020519589A (ja) Ｇ１２ｃ変異型ｒａｓタンパク質を阻害するヘテロアリール化合物
EP3154978B1 (fr) Dérivés de pyrazolopyrimidine utiles comme inhibiteurs de la tyrosine kinase de bruton
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
PT1636236E (pt) Derivados de pirazol-quinazolina, processo para sua preparação e sua utilização como inibidores de cinase
KR102700664B1 (ko) Cdk8/19 저해제로서 새로운 헤테로사이클릭 화합물
EP4161657A1 (fr) Inhibiteurs des kinases du récepteur du facteur de croissance des fibroblastes
HK40046173A (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
HK1236526B (en) Pyrazolopyrimidine derivatives useful as inhibitors of bruton's tyrosine kinase
HK1236526A1 (en) Pyrazolopyrimidine derivatives useful as inhibitors of bruton's tyrosine kinase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140505

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160628

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170706

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 952264

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171215

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: STOLMAR AND PARTNER INTELLECTUAL PROPERTY S.A., CH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012040606

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2660265

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180321

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20171206

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180306

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 952264

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180306

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180307

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012040606

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

26N No opposition filed

Effective date: 20180907

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181004

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20121004

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171206

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180406

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20221025

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20221020

Year of fee payment: 11

Ref country code: IE

Payment date: 20221027

Year of fee payment: 11

Ref country code: GB

Payment date: 20221027

Year of fee payment: 11

Ref country code: ES

Payment date: 20221102

Year of fee payment: 11

Ref country code: DE

Payment date: 20221027

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20221116

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012040606

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20231004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231004

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231031

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240501

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231004

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20241126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231005